DR. FRANK BEDU-ADDO

Immunotherapies such as our Versamune® platform products that can activate large quantities of tumor-attacking killer T-cells, and also our novel tumor-targeting cytokine are key advancements in cancer treatment. We’re excited to advance our lead candidate into a Phase 3 global registrational trial later this year.